HIV-infected infants develop broadly neutralizing plasma responses with more rapid kinetics and lower somatic hypermutation than adults, suggesting the ontogeny of infant responses could inform a better path to achievable vaccine targets. We previously isolated BF520.1, the first and only infant-derived broadly HIV-neutralizing antibody (bnAb). A thorough investigation of how BF520.1 developed will highlight possible pathways of rapid bnAb development that may be useful in vaccine design. Furthermore, resolving the structural basis of BF520.1’s interaction with HIV envelope will inform the design of effective vaccine immunogens.
We sequenced antibody genes from a blood sample collected midway between HIV infection and the isolation of BF520.1. We developed robust computational methods to reconstruct the developmental lineage of BF520.1 that include using personalized germline gene sets to infer the antibody sequences of BF520.1’s naïve ancestor, identifying midpoint sequences that were clonally-related to BF520.1, and phylogenetically determining likely mutational pathways that generated the mature bnAb. We compared our Bayesian lineage reconstruction approach to lineage inference by maximum likelihood, a common approach in the field. Lastly, we used single particle cryo-electron microscopy to explore the structural interaction of BF520.1 with the HIV envelope trimer BG505.SOSIP.664.
We computationally validated that our method of lineage reconstruction was more accurate than maximum likelihood at identifying ancestral sequences for simulated antibody lineages similar to BF520.1. Our inferred naïve precursor bound HIV Env with a KD of 46μM. A bnAb evolved within six months of infection and required only 3% somatic hypermutation. Kappa chain substitutions were critical for bnAb functionality, validated by the observation of extensive contacts between the CDRL1 loop and the N332 glycan in our 4.8Å cryo-EM map. For the heavy chain, CDRH1 and CDRH2 mutations were important for developing breadth and potency.
Overall, the developmental pathway of this infant antibody includes features distinct from adult antibodies, including several that may be amenable to better vaccine responses. Our analysis highlights the importance of considering both the heavy and light chain in the development of HIV-specific bnAbs and the fact that light chain specificity can potentially be harnessed to develop vaccine approaches that elicit such bnAbs with relatively little mutation.